PI Industries Ltd

However, revenue from operations grew marginally by 0.17% YoY to Rs 1,900.8 crore in the quarter ended 31 December 2024. Domestic revenues grew by 5% YoY, with volume up by approximately 7%. Biological products' drove growth, with revenue increasing by 20% YoY. Agchem exports saw a growth of approximately 2% with volume growth of 5%. The performance of new products was a key contributor, with revenue from new products growing by around 40% YoY. Pharma exports contributed approximately 4% of the overall exports. The firm's increase in overheads was attributed to promotion expenses for the launch of new products, as well as adding resources to build the Pharma2 business and integrate PHC. EBITDA redused by 8% to Rs 512.2 crore in Q3 of FY25 from Rs 555 crore in the same quarter last year. EBITDA margin reduced to 27% in Q3 FY25 as against 29% recorded in Q3 FY24. Gross margin declined to 53% in Q3 FY25, down from 54% in Q3 FY24, a reduction of approximately 85 bps YoY. On a nine-month basis, the company's consolidated net profit advanced 1.35% to Rs 1,329.7 crore on a 4.49% rise in revenue from operations to Rs 6,190.7 crore in 9M FY25 over 9M FY24. PI Industries operates in the domestic agricultural inputs and custom synthesis manufacturing (CSM) exports segments. It is a leading player in the domestic agricultural inputs sector, primarily dealing in agrochemicals and plant nutrients. Powered by Capital Market - Live

Net profit of P I Industries declined 16.92% to Rs 372.70 crore in the quarter ended December 2024 as against Rs 448.60 crore during the previous quarter ended December 2023. Sales rose 0.17% to Rs 1900.80 crore in the quarter ended December 2024 as against Rs 1897.50 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1900.801897.50 0 OPM %26.9429.18 - PBDT579.80604.10 -4 PBT480.70525.80 -9 NP372.70448.60 -17 Powered by Capital Market - Live

PI Industries announced that the Board of Directors of the Company at its meeting held on 6 February 2025, inter alia, have recommended the interim dividend of Rs 6 per equity Share (i.e. 600%) , subject to the approval of the shareholders.Powered by Capital Market - Live

PI Industries will hold a meeting of the Board of Directors of the Company on 6 February 2025.Powered by Capital Market - Live

Revenue from operations grew 4.91% YoY to Rs 2,221 crore in the quarter ended 30 September 2024. Domestic revenues showed a subdued performance, declining by approximately 5% YoY due to reduced supply to institutional customers. However, revenue from branded products grew by around 7% YoY, driven by a 12% increase in volume, though partially offset by a 5% decline in prices. The growth in the company's biologicals products was a key driver, with revenue increasing by approximately 18% YoY. Agchem exports saw a growth of approximately 10%, primarily driven by volume growth. The performance of new products was a key contributor, with revenue from new products growing by around 42% YoY. Pharma exports contributed Rs 411 million to the total export revenue, accounting for approximately 2% of the overall exports. The firm's overheads increased attributable to the scale-up of exports and promotion expenses for the launch of new products, which rose by approximately 14%, as well as the growth in the pharma business, which contributed to a 6% increase in overhead costs. EBITDA improved by 14% to Rs 6,289 crore in Q2 FY25 from Rs 5,534 crore in same quarter last year. EBITDA margin increased to 28% in Q2 FY25 as against 26% recorded in Q2 FY24. Gross Margin improved to 52%, an improvement of around 519 bps YoY mainly on account of better product mix and operative leverage. On half year basis, the company's consolidated net profit jumped 10.84% to Rs 957 crore in H1 FY25 as compared to Rs 863.4 crore recorded in H1 FY24. However revenue from operations grew 6.25% YoY to Rs 4,289.9 crore in H1 FY25. PI Industries operates in the domestic agricultural inputs and custom synthesis manufacturing (CSM) exports segments. It is a leading player in the domestic agricultural inputs sector, primarily dealing in agrochemicals and plant nutrients. The scrip fell 5.35% to Rs 4,210.95 on the BSE. Powered by Capital Market - Live

Net profit of P I Industries rose 5.76% to Rs 508.20 crore in the quarter ended September 2024 as against Rs 480.50 crore during the previous quarter ended September 2023. Sales rose 4.92% to Rs 2221.00 crore in the quarter ended September 2024 as against Rs 2116.90 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2221.002116.90 5 OPM %28.2826.05 - PBDT742.60592.50 25 PBT662.80512.20 29 NP508.20480.50 6 Powered by Capital Market - Live

PI Industries will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

Sanjay Agarwal, an alumnus of Harvard Business School and an executive from Wharton Business School, is also a rank holder Chartered Accountant and Cost Accountant with over 25 years of experience in corporate finance, investment banking and consumer goods industry. In his last corporate role as the Chief Financial Officer of Jyothy Labs Limited, a leading FMCG company, his varied experience and deep financial expertise led to immense value creation for the organization. PI Industries operates in the domestic agricultural inputs and custom synthesis manufacturing (CSM) exports segments. It is a leading player in the domestic agricultural inputs sector, primarily dealing in agrochemicals and plant nutrients. The pesticides maker registered 17.21% increase in consolidated net profit to Rs 448.8 crore on 8.3% rise in revenue to Rs 2,068.9 crore in Q1 FY25 as compared with Q1 FY24. The scrip declined 0.42% to currently trade at Rs 4,403.85 on Monday, 26 August 2024.Powered by Capital Market - Live

P I Industries announced that the acquisition of Plant Health Care Plc, a UK incorporated company traded on AIM, a market operated by the London Stock Exchange by PI Industries Management Consultancies L.L.C., a wholly owned subsidiary of the Company (PI LLC) by means of a court-sanctioned scheme of arrangement has been completed. With effectiveness of the Scheme, Plant Health Care Plc has become wholly owned subsidiary of PI LLC and a step down subsidiary of the Company, on and from 20 August 2024. Powered by Capital Market - Live

Domestic revenues were subdued mainly due to delayed sowing and erratic spread of monsoon although favourable product mix and improved working capital management helped in containing the financial impact. Biologicals products improved growth and revenue increase by about 39% YoY. 14% growth in Agchem exports were mainly driven by volumes and growth of new products, which was 24% YoY. Pharma contributed exports revenue of Rs 25.3 crore, dipped due to supply deferment of a few products. The firm's overheads increase attributable to the scale-up of exports and promotion expenses for the launch of the new products (11%) and newly acquired Pharma businesses (5%). EBITDA improved by 24% to Rs 585.3 crore in Q1 FY25 from Rs 472.6 crore in same quarter last year. Gross margin and EBITA margin for June 2024 quarter were at 52% (up 526 bps YoY) and 28% (up 356 bps YoY), respectively. The company's Gross Margin and EBITDA improved mainly on account of favorable product mix and operating leverage. PI Industries operates in the domestic agricultural inputs and custom synthesis manufacturing (CSM) exports segments. It is a leading player in the domestic agricultural inputs sector, primarily dealing in agrochemicals and plant nutrients. Powered by Capital Market - Live